Last updated on July 2019

An Extension Study of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Nasal polyp | Chronic Rhinosinusitis
  • Age: Between 18 - 75 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Ability to comply with the study protocol, in the investigator's judgment
  • Participation in Study GA39688 or GA39855, including completion of endoscopy and other assessments at Week 24, without discontinuation of study drug
  • Completion of eDiary daily assessments for at least 4 out of 7 days in the week prior to the Week 24 visit of Study GA39688 or GA39855
  • For women of childbearing potential: agreement to remain abstinent or use acceptable contraceptive methods during the treatment period and for 60 days after the last dose of study drug

Exclusion Criteria:

  • Anaphylaxis/hypersensitivity related to study drug in Study GA39688 or GA39855
  • Serious adverse events related to study drug in Study GA39688 or GA39855 that the investigator or Sponsor determines may jeopardize the patient's safety if he or she continues in the study
  • Uncontrolled epistaxis within Study GA39688 or GA39855
  • Pregnant or breastfeeding, or intending to become pregnant during the study or within 60 days after the last dose of omalizumab
  • Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.